-
Salix purchase of Santarus completed
RALEIGH, N.C. — Salix Pharmaceuticals has completed its $2.6 billion acquisition of Santarus, Salix said.
The drug maker announced that it had completed the $32-per-share acquisition of Santarus, which the companies announced in November. The combination of the companies' product portfolios includes 22 marketed products, such as Xifaxan, Glumetza, Zegerid, Relistor and others.
-
IMS Health files with SEC for initial public offering
DANBURY, Conn. — IMS Health is looking to go public, the healthcare industry research and analytics company said.
IMS, based in Danbury, Conn., said it had filed with the Securities and Exchange Commission for a proposed initial public offering of its common stock, adding that it had not yet determined the number of shares to be offered or the price range of the offering.